Introduction {#s1}
============

Lung clearance index (LCI) is increasingly used as an outcome measure in respiratory diseases such as cystic fibrosis (CF) \[[@C1]--[@C3]\]. Even in mild disease with well-preserved spirometry, LCI may be abnormal \[[@C4]\] indicating more sensitive detection of early disease. Continued improvements in CF health have necessitated more sensitive measures of lung function, therefore, understanding LCI is essential for both clinical practice and outcome measures for clinical trials \[[@C3]\].

LCI is derived from the multiple-breath washout (MBW) test and is calculated by dividing the cumulative expiratory volume over the washout test, by functional residual capacity (FRC). MBW can be performed either with a tracer gas such as sulfur hexafluoride (SF~6~), or can use 100% oxygen to wash out resident nitrogen (N~2~). The arbitrary end-point of 1/40th of the starting concentration (LCI~2.5~) is the historical limit of the gas analysers to assess gas mixing and 1/20th (LCI~5~) has been used to shorten the testing time by cutting the end of the washout period to increase feasibility in complex patients \[[@C5]\]. Different MBW technologies are in use; the gold standard is considered to be the respiratory mass spectrometer (RMS) \[[@C6]\]. This measures all gases directly but is expensive, nonportable and challenging to maintain. Alternative devices are now available but there are significant differences between MBW and LCI results when comparing washout of N~2~ and SF~6~ \[[@C7]\]. Currently, neither the 2013 European Respiratory Society (ERS)/American Thoracic Society (ATS) MBW consensus statement, nor the 2018 pre-school MBW ATS statement recommends a specific device or washout gas over others \[[@C6], [@C8]\]. It is only in infant testing that there is a clear mechanism for a discrepancy between test gases (change in breathing pattern and movement of O~2~ across the alveolar capillary membrane), leading to the suggestion that SF~6~ testing should be used in this cohort \[[@C9]\]. In CF and healthy control (HC) children (age 3--18 years) N~2~-derived LCI and FRC results were higher when compared with SF~6~ \[[@C7]\] but the mechanism behind this and the impact on result interpretation is still unclear. Possible explanations include equipment, physiological discrepancies between test gases \[[@C6]\] and dissolved N~2~ additionally contributing to the N~2~ washout \[[@C10]\].

We hypothesised that LCI would be intrinsically different for N~2~ than SF~6~ rather than related to equipment differences and that the results would not be interchangeable. We aimed to better understand the difference between the MBW results from N~2~ and SF~6~ in HCs and patients with CF with the following objectives: 1) Complete a comparison study with both paediatric and adult participants to confirm gas differences.2) Complete a simultaneous washout on both devices to identify whether the washout trace was the same for both gases.3) Complete exploratory testing using the RMS to identify possible equipment influences.

Materials and methods {#s2}
=====================

Study design {#s2a}
------------

### Comparison of independent MBW devices {#s2a1}

MBW measurements were performed in children and adults with CF and HCs. All of the participants (47 with CF and 42 HCs) took part in a straightforward comparison study of the Exhalyzer D (Eco Medics AG, Duernten, Switzerland), N~2~ washout (N~2~ExD~~) \[[@C7]\] and the modified Innocor gas analyser (Innovision, Odense, Denmark) SF~6~ washout (SF~6~Inn~~) \[[@C11]\]. At least two washout trials per participant were completed in all tests and sections of this study.

### Simultaneous washout of SF~6~Inn~~ and N~2~ExD~~ {#s2a2}

13 participants (5 with CF and 8 HCs) completed simultaneous washouts using the commercial equipment (Innocor and Exhalyzer D) attached in series. To minimise software bias, only end-tidal gas concentrations (C~ET~), breath number and time to the washout end-point were utilised for analysis.

### RMS: simultaneous washout {#s2a3}

10 HCs also completed simultaneous washouts using the commercial equipment attached in series with the RMS (AMIS 2000, Odense, Denmark). Again, only C~ET~, breath number and time to washout were utilised for analysis. The study sections are summarised in [figure 1](#F1){ref-type="fig"}.

![Flow diagram of overall study design, including each section, devices used and participants. MBW: multiple-breath washout; CF: cystic fibrosis; HC: healthy control; RMS: respiratory mass spectrometer.](00234-2018.01){#F1}

Study subjects {#s2b}
--------------

Subjects with CF, selected from routine clinic visits at the Royal Brompton Hospital, (RBH), UK, had a confirmed diagnosis \[[@C12]\] and were clinically stable (no pulmonary exacerbations and no irregular symptoms within 2 weeks). HC subjects with no history of airways disease or smoking were recruited from amongst patients\' family members or staff allied to Imperial College, London or RBH. All subjects were over 5 years of age.

Spirometry results were collected on patients with CF according to the ERS/ATS guidelines \[[@C13]\] using the Global Lung Initiative reference ranges \[[@C14]\].

This study was approved by the South East Coast Research Ethics Committee (number 10/H1101/69) and conducted in the clinical research facility at RBH between July 2015 and July 2017. Informed written consent and age-appropriate assent was obtained from each parent, guardian and/or participant respectively. Data were analysed as part of a PhD at Imperial College, London.

Comparison of independent MBW devices {#s2c}
-------------------------------------

Two MBW devices were used as previously reported; the N~2~ExD~~ \[[@C7]\] and the SF~6~Inn~,~ \[[@C11]\]. In brief, patients with CF and HCs completed at least two MBW trials on each, during the same test occasion in a random order generated using a random number from an Excel (Microsoft, Washington, USA) spreadsheet. Analysis was performed on specialist software (custom-built offline analysis within Simplewashout for Inn (IGOR Pro, Wavemetrics, version 6.20B3) \[[@C15]\] or online using Spiroware (version 3.1.6.17312) for ExD). The washouts were compared at the conventional cut-off of 1/40th (LCI~2.5~) of the starting end-tidal tracer gas concentration as well as the earlier 1/20th (LCI~5~) cut-off. Further device set-up, specifications and comparisons can be found in the [online supplement (OLS)](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00234-2018.figures-only#fig-data-supplementary-materials).

Simultaneous washout of SF~6~Inn~~ and N~2~ExD~~ {#s2d}
------------------------------------------------

We undertook simultaneous, breath-by-breath comparisons of SF~6~ and N~2~ washouts. We attached the SF~6~Inn~~ and N~2~ExD~~ in series, connecting flow meters using airtight plastic tubing ([figure 2](#F2){ref-type="fig"}, total dead space 73.3 mL). Tidal breathing of 0.2% SF~6~ in wash-in was followed by washout of both N~2~ and SF~6~ with 100% O~2~. The washout was extended for 2 min beyond the usual washout end-point of 1/40th end-tidal gas concentration. To compare washout curves, gas signals were normalised to percentages and put onto a log scale. The curves were then matched to breath number and time to the 1/40th washout end-point for both N~2~ and SF~6~. To simplify the calculations, and to remove confounding variables such as gas signal alignment, sampling frequency and different apparatus dead spaces, we only looked at the C~ET~. These were identified using the individual device C~ET~ detection methods (see OLS).

![Flowmeters of the Exhalyzer D (nitrogen; black box) and Innocor (sulfur hexafluoride; white box) were attached in series with airtight plastic tubing. After calibrating each device with this set-up, the gas concentration and breath number during a multiple-breath washout test were then measured simultaneously. In some cases, a respiratory mass spectrometer (RMS) gas probe was also placed between the other devices (grey dot) to read gas concentrations directly using the RMS.](00234-2018.02){#F2}

RMS: simultaneous washout {#s2e}
-------------------------

To exclude the influence of device-specific differences in gas concentration measurement, an RMS sample line was fixed in place during the simultaneous washout set-up ([figure 2](#F2){ref-type="fig"}), this also enabled comparison of all devices. A 1% SF~6~ gas mix with 21% O~2~ and balance N~2~ was utilised (BOC) so that all three devices could perform their washout protocols with 100% O~2~ as the washout gas; N~2~ was measured by both RMS and ExD, and SF~6~ was measured by RMS and Inn. Gas concentration for initial and final end-tidal gas concentrations was recorded. Breath number and washout time (1/40th) for the RMS was calculated by manually averaging the C~ET~ for both SF~6~ and N~2~ using the SW software (see OLS).

Statistical analysis {#s2f}
--------------------

The study was not based on formal power calculations, as limited data were available using all techniques. Numbers were opportunistic with attempts to keep group sizes similar. Results were compared using paired *t*-tests and Bland--Altman analysis using GraphPad Prism 6 (GraphPad Software). Statistical significance was set at p\<0.05, Kolmogorov--Smirnov tests of normality were performed, 95% confidence intervals were displayed and Cohen d estimates of effect size were calculated.

Results {#s3}
=======

Comparison of independent MBW devices {#s3a}
-------------------------------------

LCI~2.5~ was significantly higher in patients with CF than HCs in both devices ([table 1](#TB1){ref-type="table"}). LCI values were higher in N~2~ExD~~ than SF~6~Inn~~ in both groups; this difference was larger in patients with CF and increased relative to LCI. The Cohen d effect size was 1.46; the coefficients of variation were not different from each other ([OLS table 3](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00234-2018.figures-only#fig-data-supplementary-materials)). The agreement between devices for LCI~2.5~ and LCI~5~ can be seen in [figures 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}. There was a significant increased bias for N~2~ that was exaggerated with worse LCI. The difference between gases was decreased in LCI~5~ (LCI calculated at an earlier time point), showing the impact on the N~2~ washout was mostly at the tail end of the washout. LCI~2.5~ and LCI~5~ values obtained from SF~6~Inn~~ and N~2~ExD~~ were tightly correlated with forced expiratory volume in 1 s (FEV~1~) (%) Z score ([OLS figures 1 and 2](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00234-2018.figures-only#fig-data-supplementary-materials)) in patients with CF. The correlation slopes differed significantly in LCI~2.5~ and were steeper with N~2~ExD~~ but this was not the case with LCI~5~.

###### 

Comparison of multiple-breath washout devices, cystic fibrosis (CF) and healthy control (HC) demographics and lung clearance index (LCI) results

                                                  **CF (n=47)**                                        **HC (n=42)**                                                                                                           
  ---------------------------- ---------------------------------------------------- ---------------------------------------------------- ----------------------------------- ------------------------ ------------------------ --------------------------------
  **Female**                                         24 (51%)                                             26 (62%)                                                                                                             
  **Age years**                                 16.05 (5.9--63.7)                                    24.32 (5.7--56.1)                                                                                                         
  **Height cm, Z-score**                      154.6±52.2, −0.07±1.1                                158.4±17.9, −0.79±1.1                                                                                                       
  **Weight kg, Z-score**                        52.2±18, 0.60±1.1                                   59.7±20.6, −0.27±1.2                                                                                                       
  **FEV~1~ % pred, Z-score**                  72.9±16.8, −2.29±1.43                                       Not done                                                                                                             
                                                  **SF~6~Inn~~**                                       **N~2~ExD~~**                           **Difference p-value**             **SF~6~Inn~~**           **N~2~ExD~~**            **Difference p-value**
  **LCI~2.5~**                               9.5±2.3 (8.82 to 10.19)                             14.0±3.7 (12.88 to 15.14)                 −4.5 (−5.2 to −3.8), p=\<0.0001     6.3±0.5 (6.12--6.5)     7.3±0.72 (7.03--7.48)    −0.9 (−1.1 to −0.7), p\<0.0001
  **LCI~5~**                                  6.8±1.4 (6.38 to 7.23)                               7.9±1.7 (7.31 to 8.32)                  −1.01 (−1.2 to −0.8), p\<0.0001    5.1±0.4 (4.97 to 5.20)   5.1±0.3 (5.01 to 5.20)   −0.02 (−0.12 to 0.08), p=0.709
  **FRC~2.5~ L**                              1.9±0.6 (1.73 to 2.09)                               2.5±0.9 (2.23 to 2.78)                  −0.6 (−0.7 to −0.5), p\<0.0001      2.3±0.8 (2.05--2.55)     2.5±0.9 (2.25--2.84)    −0.2 (−0.3 to −0.2), p\<0.0001
  **CEV** **L**                               18.4±7.7 (16.1--20.8)                                38.5±18.7 (33.9--44.2)                 −20.1 (−23.9 to −16.3), p\<0.0001   14.5±5.6 (12.8--16.2)    19.8±7.9 (17.4--22.3)    −5.3 (−6.4 to −4.2), p\<0.0001
  **SF~6~Inn~~**                Mean LCI difference 3.2±0.4 (2.5 to 3.9) p\<0.0001                                                                                                                                             
  **N~2~ExD~~**                                                                      Mean LCI difference 6.8±0.6 (3.6 to 7.9) p\<0.0001                                                                                        

Results show mean±[sd]{.smallcaps} or median (range) with 95% confidence intervals for LCI~2.6~ and functional residual capacity (FRC). FEV~1~: forced expiratory volume in 1 s; HC: healthy control; LCI: lung clearance index; LCI~2.5~: lung clearance index calculated from washout to 1/40th of the tracer gas starting concentration; LCI~5~: lung clearance index calculated from washout to 1/20th of the tracer gas starting concentration; FRC: Functional Residual Capacity; CEV: Cumulative Expiratory Volume; MBW: multiple-breath washout; N~2~ExD~~: Exhalyzer D nitrogen device; SF~6~Inn~~: modified Innocor sulfur hexafluoride device.

![Bland--Altman plot of the difference in lung clearance index taken from the traditional end-point of 1/40th of the starting concentration (LCI~2.5~) between Exhalyzer D (nitrogen (N~2~ExD~~)) and Innocor (sulfur hexafluoride (SF~6~Inn~~)) in a) participants with cystic fibrosis (CF) and b) healthy control (HC) participants. The solid line is the mean difference between devices (4.5 in CF and 0.92 in HC) and the dotted lines represent the limits of agreement (0.08--8.92 in CF and −0.38--2.22 in HC). The difference between devices becomes disproportionately larger with a higher (worse) LCI.](00234-2018.03){#F3}

![Bland--Altman plots of the difference in lung clearance index (LCI) taken from the 1/20th end-point of the starting concentration (LCI~5~) between Exhalyzer D (nitrogen (N~2~ExD~~)) ExD) and Innocor (sulfur hexafluoride (SF~6~Inn~~)) in a) participants with cystic fibrosis (CF) and b) healthy control (HC) participants. The solid line is the mean difference between devices (1.0 in CF and 0.01 in HC) and the dotted lines represent the limits of agreement (−0.48--2.49 in CF and −0.59--0.62 in HC). The difference between devices becomes disproportionately larger with a higher (worse) LCI. The difference in LCI~5~ is not as large as the difference in LCI~2.5~.](00234-2018.04){#F4}

Simultaneous washout of SF~6~Inn~~ and N~2~ExD~~ {#s3b}
------------------------------------------------

Overall, eight HCs and five patients with CF (for full demographic data see [OLS table 2](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00234-2018.figures-only#fig-data-supplementary-materials)) performed a simultaneous washout of 0.2% SF~6~ and N~2~ using 100% O~2~ with the SF~6~Inn~~ and N~2~ExD~~ attached in series. Clearance of test gas to 1/40th occurred after fewer breaths for SF~6~ than N~2~ in patients with CF (24.8±8.7 *versus* 59.5±28.3 breaths, p=0.063) and HCs (32.0±11.9 *versus* 46.3±13.7 breaths, p=0.001; [OLS table 3)](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00234-2018.figures-only#fig-data-supplementary-materials).

[Figure 5](#F5){ref-type="fig"} shows the decline in tracer gases from one individual with CF; SF~6~ and N~2~ declined similarly at the beginning of the washout but separated beyond ∼20 breaths. SF~6~ continued linearly downwards on the log scale, whereas N~2~ curved to a plateau from which it did not decline any further. In all patients, SF~6~ reached the end target first. N~2~ seemed to reach an average asymptote concentration of 1.26%±0.09 in HCs and 1.48%±0.12 in patients with CF, whereas SF~6~ continued down to zero.

![Graph of an individual cystic fibrosis patient\'s gas concentration decline throughout a simultaneous washout of sulphur hexafluoride and nitrogen *versus* breath number. The gases are displayed in a normalised log scale for ease of visualisation. The vertical lines (dashed: SF~6~; solid: N~2~) represent the end-tidal gas concentration at 1/40th of the starting concentration; beyond this point is the extended washout period.](00234-2018.05){#F5}

RMS: simultaneous washout {#s3c}
-------------------------

Overall, 10 HC participants (for full demographic data see [OLS table 2](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00234-2018.figures-only#fig-data-supplementary-materials)) performed simultaneous washout of both SF~6~ and N~2~ on the RMS; both of the other two devices were connected to allow a direct comparison. SF~6~ washout using the RMS is typically performed using 4% SF~6~, and using 1% SF~6~ led to an increased noise-to-signal ratio, particularly at the low SF~6~ concentrations found at the end of washout. Despite the signal issues and small sample number, using RMS as the gas analysis tool, N~2~ was still slower and required a greater number of breaths to wash out than SF~6~ (34.5±12.4 *versus* 45.8±19.1 breaths, p=0.005). There were no differences in paired analysis of SF~6~ or N~2~ breaths to washout between the RMS and the Inn or ExD (RMS N~2~ 45.8±19.0 *versus* ExD N~2~ 46. 8±19.4, p≥0.05 and RMS SF~6~ 34.5±12.4 *versus* Inn SF~6~ 36.8±13.9, p\>0.05; [OLS figures 3 and 4](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00234-2018.figures-only#fig-data-supplementary-materials)).

Discussion {#s4}
==========

The primary purpose of this study was to further explore the differences in washout between N~2~ and SF~6.~ LCI derived from N~2~ was consistently higher than LCI derived from SF~6~; and this is the largest LCI difference between N~2~ and SF~6~ reported to date, which is probably due to the wide range of age and disease severity in this group of patients, indicating underlying disease pathology. Increased ventilation heterogeneity and potential gas trapping will probably further magnify differences between the two techniques. By viewing the LCI result at an earlier time point (LCI~5~) the discrepancy between gases was decreased, showing that the impact of the difference was mainly at the tail end of the washout. There are a number of possible explanations for this discrepancy, including inherent tracer and washout gas properties \[[@C16]\], tissue N~2~ and trapped N~2~ additionally contributing to the washout trace \[[@C7], [@C8], [@C17]\] and differences between equipment and analysis \[[@C18], [@C19]\].

Different physical properties of the gases could contribute to differences in washout efficiency \[[@C16]\]. SF~6~ is a dense gas and will behave differently within the lung to N~2~. The N~2~ diffusion front will be more proximally placed within the acinus, which should reduce LCI and shorten N~2~ washout time \[[@C20], [@C21]\]. However, comparison of clinical MBW data derived from helium and SF~6~, (two gases with even larger differences in molecular weight and hence diffusivity), has not shown discrepancies at anywhere near the same magnitude \[[@C22]\]. Importantly, the effect of gas density on SF~6~ washout is in the opposite direction to this study when comparing N~2~ and SF~6~.

100% O~2~ has been shown to change breathing dynamics and respiratory drive in infants and children \[[@C10]\] and could be problematic in advanced disease, when the respiratory response to hypercarbia may have been blunted \[[@C23]\]. It is unknown when such breathing changes are not relevant, but no change in breathing pattern with 100% O~2~ was reported in children age 6--9 years \[[@C24]\]. Hence in the present study, the impact of the washout gas (room air *versus* 100% O~2~) on the N~2~ and SF~6~ discrepancy is likely to be small.

P[oncin]{.smallcaps} *et al*. \[[@C18]\] completed a comparison of two N~2~ washout devices and despite both measuring N~2~, the ExD still took longer to washout to the final end-point. Agreement improved at an earlier time point and P[oncin]{.smallcaps} *et al.* \[[@C18]\] suggest this may be because the algorithm determining nitrogen fractions (washout tracer) could be subject to signal drift and cumulative error over time, which may introduce errors with low nitrogen concentrations. We have also seen that the longevity of the washout, particularly in more severe patients, increases the magnitude of the LCI discrepancy between SF~6~ and N~2~.

Only head-to-head data during the same wash-in and washout is likely to definitively assess differences in MBW \[[@C25]\]. Our RMS simultaneous washout eliminated confounding external influences and showed that differences between N~2~ and SF~6~ washout still persist, and are therefore not purely artefacts of the indirect gas analysis method.

Our extended washout shows the N~2~ signal diverging from the SF~6~ trace and remains persistently elevated if washout continues beyond the conventional termination point (around 1--2%), whereas SF~6~ washes out in a single exponential to reach zero. This may represent the contribution from tissue N~2~ that is washed out by breathing 100% O~2~. N[ielsen]{.smallcaps} *et al.* \[[@C17]\] modelled a significant impact of increased N~2~ concentration on the last part of the concentration curve; our clinical observations that technique-related differences are more marked for LCI~2.5~ than LCI~5~ support this. N[ielsen]{.smallcaps} *et al.* \[[@C17]\] suggested that at least 20% of the measured alveolar N~2~ signal at the end of washout originated from the blood and tissues rather than the airways, and that the impact would be variable with increasing ventilation heterogeneity and dead space. Tissue N~2~ contribution may also depend on cardiac output \[[@C26]\], blood volume and N~2~ tissue stores \[[@C8], [@C27]\].

Estimated N~2~ release has been calculated from differences between SF~6~ and N~2~ MBW and body plethysmography; a tissue N~2~ correction attempted to calculate the end-tidal gas concentrations of each washout breath \[[@C28]\] as well as adjusting the final washout end-point according to the washout gas \[[@C29]\]. While correction factors reduce the impact of tissue N~2~ they do not completely eliminate the effect, so they are not currently recommended \[[@C28]\]. Using a simultaneous washout plus extra *in vitro* testing, G[uglani]{.smallcaps} *et al.* \[[@C26]\] found what they described as a technical offset error in the N~2~ExD~~. When they further corrected the N~2~ trace using this offset, SF~6~ and N~2~ washouts were similar. This may be an important explanation for some of the equipment differences seen between devices, but manufacturers have not verified the results and the test gases are still not measured directly, unlike with our RMS testing. All of these comparison studies also fail to account for any real physiological differences that may inherently exist between N~2~ and SF~6~ washouts \[[@C29]\]; lung model studies would probably help to differentiate technical and physiological factors.

Previous studies have used the same equipment to measure both SF~6~ and N~2~ at the same time but calculated SF~6~ and N~2~ indirectly (*i.e.* calculating N~2~ and SF~6~ from the measurement of O~2~, CO~2~ and argon). This study used the RMS, the only device that directly measures gas concentrations and therefore could definitively measure both gases at the same time. In the RMS simultaneous washout, N~2~ still took longer to wash out than SF~6~. Persistence of these differences in tracer gas washout suggests that the prolonged washout of N~2~ is at least partially a real phenomenon that both gases are physiologically different to one another and the difference is not simply an artefact of N~2~ devices. This is particularly true as those with more severe disease and therefore prolonged washouts may be subject to cumulative errors over time.

Using an RMS to simultaneously measure both gases during an MBW has been suggested as a viable method to elucidate gas discrepancies \[[@C28]\]. Our experiences of RMS testing, however, (variability of gas detection, low signal-to-noise ratios) suggest it is an extremely challenging approach. Nitrogen washout requires particular care and calibration as 100% O~2~ is viscous and may interfere with the readout capacity of the device. Understanding of differences between washout gases and impact on the device and output is particularly important for more widespread utility of MBW as an outcome measure.

There are some limitations to our study that deserve consideration. Our simultaneous and RMS sections were based on opportunistic numbers and therefore may have introduced a type I error. Despite this we have begun to show that using a correction factor or to ignore any differences between MBW results using different test gases would be inappropriate. For simultaneous testing, only small numbers of participants and only gas concentration and breath data were used (rather than full MBW parameters). The latter was for two reasons: 1) to remove any requirement to match flow volumes and synchronise signals which could have introduced significant errors; and 2) to overcome some differences between software algorithms and calculation of derived signals (since even small software changes have been shown to have a large impact on results \[[@C30]\]). Not all software bias will have been removed (*i.e.* C~ET~ is still calculated slightly differently on each device) but traces were visually inspected to ensure correct selection of the C~ET~ using offline software, capable of calculating both N~2~ and SF~6~ \[[@C31]\]. Online equipment capable of measuring both N~2~ and SF~6~ (Exhalyzer D version 3.2.1) was not available to the researchers at the time this study was delivered.

The large dead space in the simultaneous set-up was not ideal, as this may have changed breathing dynamics due to added resistance, although there were no noted changes in tidal volume or respiratory rate (results not shown). The serial placement of the gas sample capillaries for each device may not have been truly simultaneous, but it was a pragmatic compromise to differentiate between equipment while measuring as close as possible to the same time.

As previously highlighted, we had difficulties with the signal quality of RMS testing due to the low SF~6~ concentrations and the use of 100% O~2~. This has been a previous issue with the RMS device, where up to 70% error was found if synchronisation of flow and gas concentration was not performed and dynamic viscosity was not accounted for \[[@C32]\]. However, by using raw data we have identified averaged end-tidal gas concentrations, even if the signal quality would have been too poor for accurate integration of expired gas volumes, LCI calculation and conclusive RMS results.

We conclude that N~2~ and SF~6~ washouts are inherently different; LCIs generated were higher for N~2~ at the 2.5% end washout point. We have shown the largest differences to date, exposing software differences and disease severity as further factors to consider when completing an MBW test. Our simultaneous extended washout showed that N~2~ continues beyond that of SF~6~ and reaches a nonzero asymptote, probably revealing a contribution of tissue N~2~ which is additive to the final washout. Our RMS testing, measuring gas concentrations directly, also showed a similar N~2~ asymptote, suggesting an inherent physiological difference between gases, not just equipment or software bias that may occur between devices. Clinically, N~2~ results could be interpreted as worse ventilation heterogeneity if previous MBW testing was completed using SF~6~; misinterpretation of data should be avoided.

SF~6~ and N~2~ MBW results are different and should be viewed as such. Future work should focus on the impact of the persistence of the nitrogen signal on minimal clinically important differences.
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